Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
April 24, 2024 16:05 ET
|
Sensei Biotherapeutics
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
April 09, 2024 07:30 ET
|
Sensei Biotherapeutics
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for...
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
April 04, 2024 16:05 ET
|
Sensei Biotherapeutics
BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
March 22, 2024 07:30 ET
|
Sensei Biotherapeutics
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
March 06, 2024 07:30 ET
|
Sensei Biotherapeutics
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
February 28, 2024 07:30 ET
|
Sensei Biotherapeutics
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade - -...
Sensei Biotherapeutics to Present at Upcoming Conferences
February 07, 2024 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
January 04, 2024 07:30 ET
|
Sensei Biotherapeutics
- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in specific tumor types - - Multiple clinical milestones expected in 2024...
Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 07, 2023 07:30 ET
|
Sensei Biotherapeutics
- SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported...
Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
November 03, 2023 16:05 ET
|
Sensei Biotherapeutics
- Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose...